Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy

M. Ohta, F. Kishihara, Makoto Hashizume, H. Kawanaka, M. Tomikawa, H. Higashi, K. Tanoue, K. Sugimachi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Plasma levels and gastric mucosal contents of prostaglandin (PG) E2 and prostacyclin were determined in cirrhotic patients with portal hypertensive gastropathy (PHG), in cirrhotic patients without PHG and in healthy controls. PGE2 and 6-keto-PGF (a stable metabolite of prostacyclin) levels were measured in 30 cirrhotic patients and 10 controls, using radioimmunoassay. Of 30 cirrhotics, 13 had PHG of the fundus and the corpus. Plasma concentrations of 6-keto-PGF in the cirrhotic patients were significantly higher than in the controls (p < 0.01), but there was no significant difference between cirrhotics and controls with regard to plasma levels of PGE2. The gastric mucosal contents of 6-keto-PGF in the fundus was significantly higher in cirrhotics with PHG than those without PHG (p < 0.05) and controls (p < 0.01). However, the gastric mucosal contents of PGE2 in the fundus were not significantly different in cirrhotics with and without PHG. The gastric mucosal contents of 6-keto-PGF significantly correlated to the plasma levels (r = 0.37, p < 0.05), but there was no significant correlation between plasma levels and gastric mucosal contents of PGE2. Since prostacyclin has vasodilator and gastric acid inhibitory effects, we speculate that high contents of prostacyclin in the gastric mucosa may have some role in the pathogenesis of PHG.

Original languageEnglish
Pages (from-to)41-45
Number of pages5
JournalProstaglandins, Leukotrienes and Essential Fatty Acids
Volume53
Issue number1
DOIs
Publication statusPublished - Jan 1 1995

Fingerprint

Gastrointestinal Contents
Epoprostenol
Gastric Mucosa
Dinoprostone
Plasmas
Gastric Acid
Vasodilator Agents
Radioimmunoassay
Metabolites
Mucous Membrane
prostaglandin F1
Acids

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry
  • Cell Biology

Cite this

Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. / Ohta, M.; Kishihara, F.; Hashizume, Makoto; Kawanaka, H.; Tomikawa, M.; Higashi, H.; Tanoue, K.; Sugimachi, K.

In: Prostaglandins, Leukotrienes and Essential Fatty Acids, Vol. 53, No. 1, 01.01.1995, p. 41-45.

Research output: Contribution to journalArticle

Ohta, M, Kishihara, F, Hashizume, M, Kawanaka, H, Tomikawa, M, Higashi, H, Tanoue, K & Sugimachi, K 1995, 'Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy', Prostaglandins, Leukotrienes and Essential Fatty Acids, vol. 53, no. 1, pp. 41-45. https://doi.org/10.1016/0952-3278(95)90081-0
Ohta, M. ; Kishihara, F. ; Hashizume, Makoto ; Kawanaka, H. ; Tomikawa, M. ; Higashi, H. ; Tanoue, K. ; Sugimachi, K. / Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy. In: Prostaglandins, Leukotrienes and Essential Fatty Acids. 1995 ; Vol. 53, No. 1. pp. 41-45.
@article{bf0c0c5d8be64c77b3d7b07d9ceb5ae7,
title = "Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy",
abstract = "Plasma levels and gastric mucosal contents of prostaglandin (PG) E2 and prostacyclin were determined in cirrhotic patients with portal hypertensive gastropathy (PHG), in cirrhotic patients without PHG and in healthy controls. PGE2 and 6-keto-PGF1α (a stable metabolite of prostacyclin) levels were measured in 30 cirrhotic patients and 10 controls, using radioimmunoassay. Of 30 cirrhotics, 13 had PHG of the fundus and the corpus. Plasma concentrations of 6-keto-PGF1α in the cirrhotic patients were significantly higher than in the controls (p < 0.01), but there was no significant difference between cirrhotics and controls with regard to plasma levels of PGE2. The gastric mucosal contents of 6-keto-PGF1α in the fundus was significantly higher in cirrhotics with PHG than those without PHG (p < 0.05) and controls (p < 0.01). However, the gastric mucosal contents of PGE2 in the fundus were not significantly different in cirrhotics with and without PHG. The gastric mucosal contents of 6-keto-PGF1α significantly correlated to the plasma levels (r = 0.37, p < 0.05), but there was no significant correlation between plasma levels and gastric mucosal contents of PGE2. Since prostacyclin has vasodilator and gastric acid inhibitory effects, we speculate that high contents of prostacyclin in the gastric mucosa may have some role in the pathogenesis of PHG.",
author = "M. Ohta and F. Kishihara and Makoto Hashizume and H. Kawanaka and M. Tomikawa and H. Higashi and K. Tanoue and K. Sugimachi",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0952-3278(95)90081-0",
language = "English",
volume = "53",
pages = "41--45",
journal = "Prostaglandins Leukotrienes and Essential Fatty Acids",
issn = "0952-3278",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Increased prostacyclin content in gastric mucosa of cirrhotic patients with portal hypertensive gastropathy

AU - Ohta, M.

AU - Kishihara, F.

AU - Hashizume, Makoto

AU - Kawanaka, H.

AU - Tomikawa, M.

AU - Higashi, H.

AU - Tanoue, K.

AU - Sugimachi, K.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Plasma levels and gastric mucosal contents of prostaglandin (PG) E2 and prostacyclin were determined in cirrhotic patients with portal hypertensive gastropathy (PHG), in cirrhotic patients without PHG and in healthy controls. PGE2 and 6-keto-PGF1α (a stable metabolite of prostacyclin) levels were measured in 30 cirrhotic patients and 10 controls, using radioimmunoassay. Of 30 cirrhotics, 13 had PHG of the fundus and the corpus. Plasma concentrations of 6-keto-PGF1α in the cirrhotic patients were significantly higher than in the controls (p < 0.01), but there was no significant difference between cirrhotics and controls with regard to plasma levels of PGE2. The gastric mucosal contents of 6-keto-PGF1α in the fundus was significantly higher in cirrhotics with PHG than those without PHG (p < 0.05) and controls (p < 0.01). However, the gastric mucosal contents of PGE2 in the fundus were not significantly different in cirrhotics with and without PHG. The gastric mucosal contents of 6-keto-PGF1α significantly correlated to the plasma levels (r = 0.37, p < 0.05), but there was no significant correlation between plasma levels and gastric mucosal contents of PGE2. Since prostacyclin has vasodilator and gastric acid inhibitory effects, we speculate that high contents of prostacyclin in the gastric mucosa may have some role in the pathogenesis of PHG.

AB - Plasma levels and gastric mucosal contents of prostaglandin (PG) E2 and prostacyclin were determined in cirrhotic patients with portal hypertensive gastropathy (PHG), in cirrhotic patients without PHG and in healthy controls. PGE2 and 6-keto-PGF1α (a stable metabolite of prostacyclin) levels were measured in 30 cirrhotic patients and 10 controls, using radioimmunoassay. Of 30 cirrhotics, 13 had PHG of the fundus and the corpus. Plasma concentrations of 6-keto-PGF1α in the cirrhotic patients were significantly higher than in the controls (p < 0.01), but there was no significant difference between cirrhotics and controls with regard to plasma levels of PGE2. The gastric mucosal contents of 6-keto-PGF1α in the fundus was significantly higher in cirrhotics with PHG than those without PHG (p < 0.05) and controls (p < 0.01). However, the gastric mucosal contents of PGE2 in the fundus were not significantly different in cirrhotics with and without PHG. The gastric mucosal contents of 6-keto-PGF1α significantly correlated to the plasma levels (r = 0.37, p < 0.05), but there was no significant correlation between plasma levels and gastric mucosal contents of PGE2. Since prostacyclin has vasodilator and gastric acid inhibitory effects, we speculate that high contents of prostacyclin in the gastric mucosa may have some role in the pathogenesis of PHG.

UR - http://www.scopus.com/inward/record.url?scp=0029039674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029039674&partnerID=8YFLogxK

U2 - 10.1016/0952-3278(95)90081-0

DO - 10.1016/0952-3278(95)90081-0

M3 - Article

VL - 53

SP - 41

EP - 45

JO - Prostaglandins Leukotrienes and Essential Fatty Acids

JF - Prostaglandins Leukotrienes and Essential Fatty Acids

SN - 0952-3278

IS - 1

ER -